Columns The MS Wire - A Column by Ed Tobias MS News That Caught My Eye: Diagnostic Blood Test, Fatigue, New Trials and Stem Cell Therapy MS News That Caught My Eye: Diagnostic Blood Test, Fatigue, New Trials and Stem Cell Therapy by Ed Tobias | September 25, 2017 Share this article: Share article via email Copy article link IQuity Taking Orders for RNA-based Blood Test That Can Detect MS Early with 90% Accuracy Can it be that there’s now a blood test that can help diagnose MS? This company says it has one and doctors can order it. For a disease that’s always been difficult to diagnose, as Carolina Henriques writes, this could be a “game changer.” (Carolina has also written the next two stories of interest). The life science tech company IQuityĀ has begun taking orders from physicians for an RNA-based blood test, it reports, that can provide reliable yes or no resultsĀ for multiple sclerosisĀ in seven days ā dramatically faster than previous options, which took months or years. The test, IsolateMS, can be a game-changer in diagnosing MS when administered at the start of symptoms, the company said.Ā Currently, diagnostics for MS rely on measuring the progress of irreversible neurological damage. **** Winner of $4.9 Million Research Award Tests Online and Teleconference-based Methods to Reduce MS-related Fatigue I could joke that I’m too tired to write about this, but fatigue is no joking matter to many of us with MS. So, the idea that someone is researching a program to reduce fatigue without a patient having to travel anywhere to be treated is something I want to learn more about. This research is just getting started, so I’ll be watching with great interest. People with MSĀ often face geographic barriers that end up limiting their treatment options. That has led a Case Western Reserve University researcher to test online- and teleconference-based methods of reducing fatigue and improving patientsā quality of life. Matthew Plow, assistant professor at the universityās Frances Payne Bolton School of Nursing in Cleveland, Ohio, recently won aĀ $4.9 million award from the Patient-Centered Outcomes Research Institute (PCORI)Ā for his four-year project. **** TG Therapeutics Recruiting Patients for Two Phase 3 Trials of Relapsing MS Therapy TG-1101 TG-1101 is one of the newest type of disease modifying therapies. These therapies use a monoclonal antibody that targets B-cells that carry the CD20 protein. Those are the “rogue” cells that are thought to attack the myelin of MS patients. (Ocrevus is a drug that acts similarly). TG TherapeuticsĀ is recruiting participants for two Phase 3 clinical trials that will evaluate the safety and effectiveness of TG-1101 (ublituximab)Ā as a treatment for relapsing forms of multiple sclerosis. ULTIMATE 1 (NCT03277261) and ULTIMATE 2 (NCT03277248) will compare TG-1101, aĀ glycoengineered monoclonal antibody, with GenzymeāsĀ Aubagio (teriflunomide) in relapsing MS patients. Relapsing MS is a term that covers bothĀ relapsing/remitting MS (RRMS)Ā andĀ secondary progressive MS (SPMS)Ā with relapses. **** ImStem, UConn Obtain U.S. Patent for Mesenchymal Stem Cell Technology to Treat MS, Other Diseases The researchers who’ve received this patent say their stem cell technology has the potential to offer strong immunosuppression and tissue regeneration with no side effects. In addition, they say it will be more robust and less expensive than other adult stem cell therapies. It’s still very early in the game but, as Alice MelĆ£o writes, animal tests have been positive. The U.S. Patent and Trademark OfficeĀ has issued a patent for human embryonic stem cells derived mesenchymal stem cells, called hES-T-MSC or T-MSC, for their method of production. This newly patented technology was developed by ImStem Biotechnology in collaboration with theĀ University of Connecticut (UConn) to advance new therapies for MSĀ and other autoimmune diseases. The hES-T-MSCs have theĀ potential to treatĀ autoimmune disorders caused in part by increased reactivity of immune T-cells. These stem cells ā discovered by Dr. Ren He Xu, former director of UConn Stem Cell Core, and Dr. Xiaofang Wang ā are of particular interest for MS. *** Note:Ā Multiple Sclerosis News TodayĀ is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those ofĀ Multiple Sclerosis News Today, or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to multiple sclerosis. Print This Page About the Author Ed Tobias People say to write what you know and Ed Tobias knows about MS. He's lived with the illness since 1980, when he was 32 years old. Ed's a retired, award-winning broadcast journalist and his column combines his four decades of MS experiences with news and comments about the latest in the MS community. In addition to writing his column, Ed is one of the patient moderators on the MS News Today Facebook, Twitter, and Instagram sites. Heās also the author of āThe Multiple Sclerosis Toolbox: Hints and Tips for Living with M.S.ā Ed and his wife split their time between the Washington, D.C. suburbs and Floridaās Gulf Coast, trying to follow the sun. Tags blood test, MS fatigue, stem cell, TG-1101 Comments charles any news about a tolerogenic strategy using myelin antigens? i do recall reading about polyionic nanoparticles containing myelin antigen and rapamycin which are injected into lymph nodes to force tolerance. why is this not getting more buzz? did it fail a clinical trial? i also recall reading about a study using fusion proteins of reovirus protein sigma one with fragments of myelin proteins. if i remember correctly, that was just tried in rodents, but it worked well. there were some aspects of the study design that admittedly could have been designed better, but the concept is still sound. Reply Chas I am leaving to go get this done in Panama and wondering if you meant to state umbilical chord instead of embrionic. Reply Cheramie How did you make the contact for having this done in Panama??? Reply Leave a comment Fill in the required fields to post. Your email address will not be published. Your Name Your Email Your Comment Post Comment
March 18, 2024 News by Lindsey Shapiro, PhD Cell therapy using Tregs in MS headed to Phase 2 trials in Poland